4-Amino-2-dimethylaminochinazolin | 40172-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-Amino-2-dimethylaminochinazolin
• 英文别名: N²,N²-dimethyl-quinazoline-2,4-diamine；4-Amino-2-dimethylaminoquinazoline；2-N,2-N-dimethylquinazoline-2,4-diamine
• CAS: 40172-75-6
• 化学式: C₁₀H₁₂N₄
• 分子量: 188.232
• InChiKey: YPINGHVENXGMOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-chloro-2-N,N-dimethylaminoquinazoline 在 氨 作用下， 生成 4-Amino-2-dimethylaminochinazolin
  参考文献：
  名称：

  Kokel, Bruno, Heterocycles, 1984, vol. 21, # 2, p. 709

  摘要：

  DOI：

文献信息

• [EN] NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF<br/>[FR] NOUVEAUX DERIVES DE QUINAZOLINE ET LEUR UTILISATION THERAPEUTIQUE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2004087680A1

  公开（公告）日：2004-10-14

  The present invention relates to novel compounds of Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新型化合物，其化学式为（I），该化合物作为MCH受体拮抗剂。这些组合物在药物组合物中具有用途，包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食障碍，包括暴食症、厌食症、精神障碍，包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍，包括帕金森病、癫痫和成瘾症。
• 4-Amino-pyrimidine derivatives
  申请人：N.V. Koninklijke Pharmaceutische Fabrieken v/h Brocades-Stheeman en

  公开号：US03980650A1

  公开（公告）日：1976-09-14

  A process is described for the preparation of pyrimidine derivatives having therapeutic properties. They have the general formula: ##SPC1## Wherein A represents an alkylene or alkenylene grouping which together with the carbon atoms of the pyrimidine nucleus to which it is attached forms a homocyclic ring containing five to seven carbon atoms, which homocyclic ring may carry one or more halogen, lower alkyl and/or lower alkoxy substituents and R represents an amino, lower alkylamino or di(lower)alkylamino group, or a nitrogen-, oxygen- or sulphur-containing saturated or unsaturated mononuclear heterocyclic group linked to the pyrimidine ring either through a carbon atom or, when the group contains a nitrogen atom, either through the nitrogen atom or a carbon atom and are prepared by reacting a cycloaliphatic(A)oaminonitrile with a nitrile of the formula R-CN where A and R have the above meanings in the presence of a basic alkali metal-containing compound and then reacting the resultant intermediate with water. The compounds have heretofore undiscovered antimicrobial and antihypertensive properties.

  描述了一种制备具有治疗性质的嘧啶衍生物的过程。它们具有以下通式：##SPC1## 其中，A代表一个烷基或烯基基团，它与连接在其上的嘧啶环的碳原子一起形成一个含有五到七个碳原子的同环环，该同环环可以携带一个或多个卤素、较低的烷基和/或较低的烷氧基取代基，R代表氨基、较低的烷基氨基或双(较低)烷基氨基基团，或者是与嘧啶环连接的含氮、氧或硫饱和或不饱和的单核杂环基团，该杂环基团通过碳原子或者当基团包含氮原子时，通过氮原子或碳原子与嘧啶环连接。它们是通过在碱金属化合物存在下将环状脂肪族(A)氨基腈与式为R-CN的腈反应制备的，其中A和R具有上述含义，然后将所得的中间体与水反应。这些化合物具有迄今为止未发现的抗微生物和降压性质。
• EP1611109A1
  申请人：——

  公开号：EP1611109A1

  公开（公告）日：2006-01-04
• EP1611109A4
  申请人：——

  公开号：EP1611109A4

  公开（公告）日：2009-06-24
• Modulation of chemosensory receptors and ligands associated therewith
  申请人：Senomyx, Inc.

  公开号：EP2573559B1

  公开（公告）日：2019-03-13